I'll research PODD (Insulet) before writing the preview. Let me start by gathering recent earnings materials, filings, and news.Let me read the most recent earnings materials (Q1 2026) and the prior quarter, plus check for recent news.Now let me get the year-ago comparison quarter (Q2 2025) and recent price action and news.Let me check recent news/press releases and the competitive backdrop before writing.I now have what I need. Here's the earnings preview.
Insulet heads into its Q2 print as one of the fastest-growing large-cap medtech names, but with a stock that has spent the last four months rebuilding trust after a rough spring. Shares peaked around $207 in early April, then fell to roughly $151 by the May 6 Q1 report, with a sharp air-pocket on April 29 (from ~$183 to ~$160) tied to FDA confusion around a March device correction. The stock troughed in the low-$140s in late May/early June and has since clawed back to ~$167 (Aug 4 close) — still down ~19% from the April high but up ~17% off the lows.
Translation: expectations have reset lower, sentiment is cautiously recovering, and this print is a chance for the new management team (CEO Ashley McEvoy at ~15 months, CFO Flavia Pease, new CCO Mike Panos) to prove the Q1 U.S. softness was truly transitory.
On the Q1 call (May 6), Insulet guided Q2 2026 as follows (constant currency, ~100 bps FX tailwind to reported):
| Segment | Q2 2026 Guide (CC) | Reported | Q2 2025 Comp |
|---|---|---|---|
| U.S. Omnipod | 18–20% | 18–20% | $453.2M (+28.7%) |
| Int'l Omnipod | 28–30% | 30–32% | $185.8M (+45% rep / +38.8% cc) |
| Total Omnipod | 21–23% | 22–24% | $639.0M |
| Drug Delivery | ~(50)% | ~(50)% | $10.2M |
| Total company | 20–22% | 21–23% | $649.1M |
That math points to total revenue of roughly $785–800M, implied U.S. Omnipod of ~$535–544M, and international of ~$242–245M. For reference, Q2 2025 delivered adjusted EPS of $1.17, adjusted operating margin of 17.8%, gross margin of 69.7%, and adjusted EBITDA of $157.5M (24.3%).
Key nuance: management flagged ~$10M of distributor-order timing that pulled into Q1 and out of Q2, creating a ~200 bps headwind to Q2 U.S. growth. So the 18–20% U.S. guide is optically softer than underlying demand — worth remembering when judging the U.S. line.
This is the whole ballgame. Q1 U.S. Omnipod grew a strong 28%, but new customer starts fell sequentially, which management attributed to unusual Q1 seasonality — deductible resets hitting patient co-pays/co-insurance, plus possible ACA transition effects — rather than anything company-specific. They insisted momentum improved month-over-month through Q1 and into April.
Watch for: - NCS trajectory confirmation. Did the Q2 rebound management promised actually show up? Any hedging here would be a red flag. - Type 2 momentum. ~40% of U.S. NCS were Type 2 in Q1, with penetration still only ~5% of a ~5.5M insulin-using T2 TAM. The ADA guideline update established AID as standard of care. Management says GLP-1s are complementary, not competitive (26% of T2s remain on insulin despite 41% GLP-1 adoption). - Retention. Type 2 retention runs modestly below Type 1 (expected, but the base is growing), pulling blended U.S. retention down slightly — offset by improving international retention (total company still ~90%).
The bigger structural worry: the full-year guide implies high-teens growth in H2, and management acknowledged the U.S. likely exits 2026 below the 20% long-range target. Bears (JPMorgan, others on the Q1 call) pressed on how the ~20% LRP holds if dollar growth isn't increasing YoY and the exit rate is decelerating. Management's answer rests on 2027 catalysts (Omnipod 6, full-year benefit of the ~25% sales-force expansion done this quarter) and international/new-market tailwinds. Any commentary reinforcing or softening the 20%+ durability narrative will move the stock.
FY 2026 framework (raised at Q1): Total company 21–23% cc; U.S. 20–22% (unchanged); International raised to 26–28% cc; adj. operating margin +~100 bps; adjusted EPS growth >25%; FCF ~flat YoY; tax rate 21–22%. A guidance raise (following the Q1 beat) would be a strong signal; merely reaffirming may disappoint given the low-$140s-to-$167 recovery.
Tubeless is no longer a monopoly-in-waiting: Tandem plans to submit its tubeless Mobi to the FDA this quarter (clearance targeted H2 2026), and Sequel's twiist and Beta Bionics are active, alongside new entrants in the pharmacy channel. Insulet's pushback: it's the #1 brand, volumes are "multiples" larger than the nearest competitor, it's on its 6th-gen platform while others attempt their first, and — critically — U.S. net pricing was positive in Q1 and expected positive for the full year, with rebate behavior described as "rational and disciplined." Any crack in that pricing narrative would be the most important negative surprise this print.
The March 2026 voluntary medical device correction, and a poorly-worded late-April FDA update (NDRs misreported as SAEs), spooked the stock. Management maintains no NCS impact, no new adverse events since the April 10 update, and at the June ADA event noted physicians/patients have largely moved on. Any fresh regulatory or quality-systems commentary is a watch item but appears to be a fading risk.
With shares recovered off the lows but still well below April, the risk/reward hinges on whether Q1's U.S. softness was genuinely seasonal. A clean U.S. reacceleration plus another guidance raise would validate the recovery; any hesitation on the U.S. line or pricing would likely reopen the deceleration debate.
Sources: Insulet Q1 2026 earnings call and release (5/6/26), Q2 2025 earnings release (8/7/25), June 8, 2026 ADA investor event transcript, PODD daily price data through 8/4/26, and public reporting on competitor product timelines. Note: figures marked "implied" are my estimates derived from company guidance applied to prior-year actuals, not company or consensus forecasts.